Jiangsu Trautec
Trautec 成立于 2015 年，专注重组胶原蛋白（SRHC）生物材料的开发和生产，主要面向医疗和化妆品行业——SRHC 是以生物合成方式生产的非动物源胶原蛋白。作为行业先行者，Trautec 运营从研发、制造到分销的完整价值链：在重组胶原蛋白开发中持有多项知识产权，并在江苏拥有自有生产工厂。随着越来越多消费者寻求有效的皮肤问题解决方案，提供特定功效的功能护肤市场正显著增长；重组胶原蛋白因其稳定性、有效性以及在医疗、保健和化妆品领域的广泛应用而需求不断扩大。2022 年，资生堂 Beauty Innovation Fund 投资 Trautec，双方建立全面战略伙伴关系——在产品研发、原料供应、销售渠道到功能护肤新领域探索等各方面合作。2023 年，B 轮融资成功完成……
简介
Jiangsu Trautec Medical Technology Co., Ltd. (Trautec), founded in 2015 and headquartered in Changzhou/Jiangsu, develops, manufactures, and sells recombinant collagen-based biomaterials for medical and cosmetic/functional skincare use, operating an end-to-end biosynthesis-to-distribution chain with multiple IP patents. Core offerings/technology include SRHC types I/II/III/XVII (not animal-derived), with standardized large-scale production (e.g., 30-ton fermentation scale) and associated clinical/medical-device transformation capabilities. Shiseido’s fund led an ~RMB 100m strategic investment in 2022, and Trautec later raised RMB 200m Series B in 2023 led by L Catterton (with other investors including CLSA Capital Partners/CITIC CLSA). Reported scale details include a 100,000 sq ft headquarters facility in Jiangsu, >$17m invested in ReCol 3® production, and partnerships with 30 provincial capitals plus 1,000+ hospitals; public English sources don’t disclose revenue/employees. Key partners/customers named include Shiseido, Winona, Proya, Jala, and Sinopharm (plus >30 cosmetic/pharma companies referenced). Latest 2025-2026 developments: the provided sources only list activity through 2021-current and 2024 milestones; they do not confirm 2025-2026 status beyond those items, nor whether the company was still active in 2026. Sources:.
Sources#
- Shiseido Beauty Innovations Fund announces investment in Trautec as lead investor | NEWS RELEASE | Shiseido Company — 2022-08-10
- About
- Trautec Completes RMB 200 Million Series B Fundraise Led by L Catterton — 2023-09-28
- Chinese Collagen Tech Startup Trautec Raises USD27.4 Million — 2023-09-18
- Trautec - Products, Competitors, Financials, Employees, Headquarters Locations — 2023-09-16
- Jiangsu Trautec Medical — Whiteford Research Biobase
- Jiangsu Trautec Medical Technology Co Ltd - Company Profile and News - Bloomberg Markets
- Revolutionizing Skin Repair with Recombinant Type XVII Collagen in China’s Growing Markets
- 行业
- 化妆品
- 主题
- 透明质酸、胶原蛋白与化妆品生物活性成分
- 角色
- 生产商 — “…hangzhou/Jiangsu, develops, manufactures, and sells recombinant collagen-based biomaterials for medical and co…”
供应的生物解决方案 0
尚未被列为已评级方案的供应商。
产品与服务
该公司未公开其产品或服务——我们可通过引荐了解。
新闻与状态 6
- 2024-01 最新状态: 公司于2024年1月启动 IPO 申报流程。 ↗ ↗ ↗
- 状态核查: active — Recombinant-collagen implant approved (Dec 2025); A-share IPO preparation.
- 2025-12-23 重磅喜讯 | 创健医疗交联重组胶原蛋白植入剂正式获批_企业动态_新闻中心_江苏创健医疗科技股份有限公司江苏创健医疗科技股份有限公司（Jiangsu Trautec）宣布自主研发的“交联重组胶原蛋白植入剂”已获国家药监局批准上市，成为国内首款同类交联重组胶原蛋白植入剂，适用于面部真皮填充以纠正中重度动力性皱纹（如眉间纹、额头纹、鱼尾纹）。注册证编号为国械注准。
- 2026-03-27 PCHi announces winners of its 2026 Fountain AwardsJiangsu Trautec Medical Technology won a Gold award for their tFNA at the 2026 Fountain Awards. This highlights the company as a leading innovator in anti-wrinkle cosmetic biotechnology recognized by PCHi.
- 2025-07-16 喜讯｜创健医疗入选国家工信部第一批“AI+生物制造”典型案例 _企业动态_新闻中心_江苏创健医疗科技股份有限公司Jiangsu Trautec (创健医疗) has been selected by China's Ministry of Industry and Information Technology as part of the first batch of “AI+Biomanufacturing”典型案例, recognizing its AI-assisted design of recombinant collagen as a national benchmark for integrating AI …
- 2025-04-01 喜报 | SCI一区！创健联合珀莱雅共研成果荣登国际权威期刊 _企业动态_新闻中心_江苏创健医疗科技股份有限公司Jiangsu Trautec (创健医疗) is highlighted as a leading supplier in recombinant collagen and synthetic biology, collaborating with Jilin University of Technology and Proya to achieve a high-impact, AI-driven study on rhCOL17 published in a top journal, and …
- 2025-05-08 喜讯 | 羟基化率56%！创健医疗获I型、III型重组人胶原蛋白双专利授权_企业动态_新闻中心_江苏创健医疗科技股份有限公司Jiangsu Trautec (创健医疗) announces a major breakthrough: they have secured dual invention patents for recombinant human collagen types I and III, produced via yeast expression, with a hydroxyproline content of 56%—approaching natural human collagen and promising …
- 2025-01-20 喜讯｜GRAS权威认证！创健医疗重组胶原蛋白获得美国市场准入许可 _企业动态_新闻中心_江苏创健医疗科技股份有限公司Jiangsu Trautec (创健医疗) announces that its recombinant humanized type III collagen has earned GRAS certification, gaining entry to the U.S. market and signaling a major milestone in its global, green, biosynthetic collagen strategy.
关系网络：股东、合作伙伴、同类
股权与投资方 5
| 投资方 | Shiseido Beauty Innovations Fund |
| 投资方 | L Catterton |
| 投资方 | Boyu Capital |
| 投资方 | CDH Baifu Capital |
| 投资方 | Holley Group Co., Ltd |
合作与交易 3
| 交易对手 | Shiseido …The company initiated an IPO filing process in January 2024.… |
| 交易对手 | L Catterton …The company initiated an IPO filing process in January 2024.… |
| 交易对手 | CITIC Securities …The company initiated an IPO filing process in January 2024.… |
同类企业
Sewon Cellontech Co., Ltd. · 山西锦波生物医药股份有限公司 · Shanxi Jinbo bio-pharmaceutical Co., Ltd. · Maxigen Biotech Inc. · Nippi, Inc. · Jland Biotech · Beijing SEMNL Biotechnology Co.,Ltd. · HTL Biotechnology
身份与联系方式
联系方式、人员和法律信息仅向会员开放。
会员登录